|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Toll-like receptor 4 and NOD2/CARD15 mutations in Hungarian patients with Crohn's disease: Phenotype-genotype correlations显示文摘AIM: To determine common NOD2/CARD15 mutations and TLR4 D299G polymorphism in Hungarian patients with CD.METHODS: A total of 527 unrelated patients with CD (male/female: 265/262, age: 37.1 (SD 7.6) years) and 200 healthy subjects were included. DNA was screened for possible NOD2/CARD15 mutations by denaturing highperformance liquid chromatography (confirmed by direct sequencing). TLR4 D299G was tested by PCR-RFLP.RESULTS: NOD2/CARD15 mutations were found in 185patients (35.1%) and in 33 controls (16.5%, P<0.0001).SNP8/R702W (10.8% vs 6%, P = 0.02), SNP13/3020insC (19.4% vs 5%, P<0.0001) and exon4 R703C (2.1% vs 0%, P = 0.02) mutations were more frequent in CD, while the frequency of SNP12/G908R was not increased. The frequency of TLR4 D299G was not different (CD: 9.9% vscontrols: 12.0%). Variant NOD2/CARD15 allele was associated with an increased risk for CD (ORhet = 1.71,95%CI = 1.12-2.6, P= 0.0001, ORtwo-riskalleles = 25.2,95%CI = 4.37- , P<0.0001), early disease onset (carrier:26.4 years vs non-carrier: 29.8 years, P = 0.0006), ileal disease (81.9% vs 69.5%, OR = 1.99, 95%CI = 1.29-3.08,P = 0.02, presence of NOD2/CARD15 and TLR4: 86.7% vs64.8%), stricturing behavior (OR = 1.69, 95%CI = 1.13-2.55,P = 0.026) and increased need for resection (OR=1.71,95%CI: 1.13-2.62, P= 0.01), but not with duration, extraintestinal manifestations, familial disease or smoking. TLR4exhibited a modifier effect: age of onset in wt/TLR4 D299G carriers: 27.4 years vs NOD2mut/TLR D299G: 23 years (P= 0.06), in NOD2mut/wt: 26.7 years.CONCLUSION: These results confirm that variant NOD2/CARD15 (R702W, R703C and 3020insC) alleles are associated with earlier disease onset, ileal disease,stricturing disease behavior in Hungarian CD patients. In contrast, although the frequency of TLR4 D299G polymorphism was not different from controls, NOD2/TLR4mutation carriers tended to present at earlier age. | Peter Laszlo Lakatos Laszlo Lakatos Ferenc Szalay Claudia Willheim-Polli Christoph (O|¨)sterreicher Zsolt Tulassay Tamas Molnar Walter Reinisch Janos Papp Gyula Mozsik Hungarian IBD Study Group Peter Ferenci | 2005 | World Journal of Gastroenterology2005，11，10： | 14 |
| 2 | Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis显示文摘 | Axel Dignass Rami Eliakim Fernando Magro Christian Maaser Yehuda Chowers Karel Geboes Gerassimos Mantzaris Walter Reinisch Jean-Frederic Colombel Severine Vermeire Simon Travis James O. Lindsay Gert Van Assche | 2012 | Journal of Crohn’s and Colitis2012，，10： | 12 |
| 3 | Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis显示文摘 | William J. Sandborn Gert van Assche Walter Reinisch Jean–Frederic Colombel Geert D’Haens Douglas C. Wolf Martina Kron Mary Beth Tighe Andreas Lazar Roopal B. Thakkar | 2012 | Gastroenterology2012，，2： | 9 |
| 4 | Subcutaneous Golimumab Induces Clinical Response and Remission in Patients with Moderate-To-Severe Ulcerative Colitis显示文摘 | William J. Sandborn Brian G. Feagan Colleen Marano Hongyan Zhang Richard Strauss Jewel Johanns Omoniyi J. Adedokun Cynthia Guzzo Jean-Frederic Colombel Walter Reinisch Peter R. Gibson Judith Collins Gunnar J?rnerot Toshifumi Hibi Paul Rutgeerts | 2013 | Gastroenterology2013，，： | 6 |
| 5 | Subcutaneous Golimumab Maintains Clinical Response in Patients with Moderate-To-Severe Ulcerative Colitis显示文摘 | William J. Sandborn Brian G. Feagan Colleen Marano Hongyan Zhang Richard Strauss Jewel Johanns Omoniyi J. Adedokun Cynthia Guzzo Jean-Frederic Colombel Walter Reinisch Peter R. Gibson Judith Collins Gunnar J?rnerot Paul Rutgeerts | 2013 | Gastroenterology2013，，： | 5 |
| 6 | Burden and outcomes for complex perianal fistulas in Crohn's disease:Systematic review显示文摘AIM To systematically review the literature on epidemiology,disease burden, and treatment outcomes for Crohn's disease(CD) patients with complex perianal fistulas.METHODS PubMed, Embase, and Cochrane were searched for relevant articles(published 2000-November 2016) and congress abstracts(published 2011-November 2016).RESULTS Of 535 records reviewed, 62 relevant sources were identified(mostly small observational studies). The cumulative incidence of complex perianal fistulas in CD from two referral-centre studies was 12%-14%(follow-up time, 12 years in one study; not reported in the second study). Complex perianal fistulas result in greatly diminished quality of life; up to 59% of patients are at risk of faecal incontinence. Treatments include combinations of medical and surgical interventions and expanded allogeneic adipose-derived stem cells. High proportions of patients experience lack of or inadequate response to treatment(failure and relapse rates,respectively: medical, 12%-73% and 0%-41%; surgical:0%-100% and 11%.20%; combined medical/surgical:0%-80% and 0%-50%; stem cells: 29%-47% and not reported). Few studies(1 of infliximab; 3 of surgical interventions)have been conducted in treatment-refractory patients, a population with high unmet needs. Limited data exist on the clinical value of anti-tumour necrosis factor-α dose escalation in patients with complex perianal fistulas in CD.CONCLUSION Complex perianal fistulas in CD pose substantial clinical and humanistic burden. There is a need for effective treatments, especially for patients refractory to antitumour necrosis factor-α agents, as evidenced by high failure and relapse rates. | Julian Panes Walter Reinisch Ewa Rupniewska Shahnaz Khan Joan Forns Javaria Mona Khalid Daniela Bojic Haridarshan Patel | 2018 | World Journal of Gastroenterology2018，24，42： | 5 |
| 7 | Adalimumab Induces and Maintains Mucosal Healing in Patients With Crohn’s Disease: Data From the EXTEND Trial显示文摘 | Paul Rutgeerts Gert Van Assche William J. Sandborn Douglas C. Wolf Karel Geboes Jean–Frédéric Colombel Walter Reinisch Ashish Kumar Andreas Lazar Anne Camez Kathleen G. Lomax Paul F. Pollack Geert D’Haens | 2012 | Gastroenterology2012，，5： | 4 |
| 8 | Inflammatory Bowel Disease Is a Risk Factor for Recurrent Venous Thromboembolism显示文摘 | Gottfried Novacek Ansgar Weltermann Anna Sobala Herbert Tilg Wolfgang Petritsch Walter Reinisch Andreas Mayer Thomas Haas Arthur Kaser Thomas Feichtenschlager Harry Fuchssteiner Peter Knoflach Harald Vogelsang Wolfgang Miehsler Reingard Platzer Wolfgang T | 2010 | Gastroenterology2010，，3： | 4 |
| 9 | Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management显示文摘 | Axel Dignass James O. Lindsay Andreas Sturm Alastair Windsor Jean-Frederic Colombel Mathieu Allez Gert D’Haens André D’Hoore Gerassimos Mantzaris Gottfried Novacek Tom ?resland Walter Reinisch Miquel Sans Eduard Stange Severine Vermeire Simon Travis Gert | 2012 | Journal of Crohn’s and Colitis2012，，10： | 4 |
| 10 | European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease显示文摘 | J.F. Rahier S. Ben-Horin Y. Chowers C. Conlon P. De Munter G. D’Haens E. Domènech R. Eliakim A. Eser J. Frater M. Gassull M. Giladi A. Kaser M. Lémann T. Moreels A. Moschen R. Pollok W. Reinisch M. Schunter E.F. Stange H. Tilg G. Van Assche N. Viget B. Vu | 2009 | Journal of Crohn’s and Colitis2009，，2： | 3 |
| 11 | Transanal hybrid colon resection: from laparoscopy to NOTES显示文摘 | Karl-Hermann Fuchs Wolfram Breithaupt Gabor Varga Thomas Schulz Alexander Reinisch Nenad Josipovic | 2013 | Surgical Endoscopy2013，，3： | 3 |
| 12 | Update on pathogenesis and predictors of response of therapeutic strategies used in inflammatory bowel disease显示文摘The search for biomarkers that characterize specific aspects of inflammatory bowel disease(IBD), has received substantial interest in the past years and is moving forward rapidly with the help of modern technologies. Nevertheless, there is a direct demand to identify adequate biomarkers for predicting and evaluating therapeutic response to different therapies. In this subset, pharmacogenetics deserves more attention as part of the endeavor to provide personalized medicine. The ultimate goal in this area is the adjustment of medication for a patient's specific genetic background and thereby to improve drug efficacy and safety rates. The aim of the following review is to utilize the latest knowledge on immunopathogenesis of IBD and update the findings on the field of Immunology and Genetics, to evaluate the response to the different therapies. In the present article, more than 400 publications were reviewed but finally 287 included based on design, reproducibility(or expectancy to be reproducible and translationable into humans) or already measured in humans. A few testshave shown clinical applicability. Other, i.e., genetic associations for the different therapies in IBD have not yet shown consistent or robust results. In the close future it is anticipated that this, cellular and genetic material, as well as the determination of biomarkers will be implemented in an integrated molecular diagnostic and prognostic approach to manage IBD patients. | Emilio G Quetglas Zlatan Mujagic Simone Wigge Daniel Keszthelyi Sebastian Wachten Ad Masclee Walter Reinisch | 2015 | World Journal of Gastroenterology2015，21，44： | 3 |
| 13 | Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial显示文摘 | Paul Moayyedi Michael G. Surette Peter T. Kim Josie Libertucci Melanie Wolfe Catherine Onischi David Armstrong John K. Marshall Zain Kassam Walter Reinisch Christine H. Lee | 2015 | Gastroenterology2015，，： | 3 |
| 14 | The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Special situations显示文摘 | Gert Van Assche Axel Dignass Walter Reinisch C. Janneke van der Woude Andreas Sturm Martine De Vos Mario Guslandi Bas Oldenburg Iris Dotan Philippe Marteau Alessandro Ardizzone Daniel C. Baumgart Geert D’Haens Paolo Gionchetti Francisco Portela Boris Vuce | 2009 | Journal of Crohn’s and Colitis2009，，1： | 3 |
| 15 | Review article: the role of anti‐TNF in the management of ulcerative colitis – past, present and future显示文摘 | S. Danese J.‐F. Colombel L. Peyrin‐Biroulet P. Rutgeerts W. Reinisch | 2013 | Aliment Pharmacol Ther2013，，9： | 3 |
| 16 | Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis显示文摘 | Jean Frédéric Colombel Paul Rutgeerts Walter Reinisch Dirk Esser Yanxin Wang Yinghua Lang Colleen W. Marano Richard Strauss Bj?rn J. Oddens Brian G. Feagan Stephen B. Hanauer Gary R. Lichtenstein Daniel Present Bruce E. Sands William J. Sandborn | 2011 | Gastroenterology2011，，4： | 3 |
| 17 | Probiotika in der Pr?vention der Antibiotika-induzierten Diarrh?显示文摘 | A. Eser F. Thalhammer F. Burghuber C. H?genauer F. Stockenhuber C. Wenisch K. Widhalm W. Reinisch | 2012 | Z Gastroenterol2012，，10： | 2 |
| 18 | Clinical presentation of venous thromboembolism in inflammatory bowel disease显示文摘 | Pavol Papay Wolfgang Miehsler Herbert Tilg Wolfgang Petritsch Walter Reinisch Andreas Mayer Thomas Haas Arthur Kaser Thomas Feichtenschlager Harry Fuchssteiner Peter Knoflach Harald Vogelsang Reingard Platzer Wolfgang Tillinger Bernhard Jaritz Alfons Schm | 2012 | Journal of Crohn’s and Colitis2012，，： | 2 |
| 19 | Tissue factor exposing microparticles in inflammatory bowel disease显示文摘 | Julia Palkovits Gottfried Novacek Marietta Kollars Gregor Hron Wolf Osterode Peter Quehenberger Paul Alexander Kyrle Harald Vogelsang Walter Reinisch Pavol Papay Ansgar Weltermann | 2012 | Journal of Crohn’s and Colitis2012，，： | 2 |
| 20 | State of the iron: How to diagnose and efficiently treat iron deficiency anemia in inflammatory bowel disease显示文摘 | Walter Reinisch Michael Staun Sunil Bhandari Manuel Mu?oz | 2012 | Journal of Crohn’s and Colitis2012，，： | 2 |
您所在的机构暂未开通此部分的功能，请联系管理员